Before the pandemic, virtual and hybrid trials were a novelty. Although enabling technologies such as bring your own device (BYOD), electronic patient-reported outcomes (ePRO), and direct data capture (DDC) have been in place for several years, the implementation of these hybrid approaches stagnated. Now, remote trials are a proven and valuable necessity. Jonathan Andrus at Clinical Ink discusses practical considerations in virtual and hybrid trials and how these trials can help reduce cost, deliver cleaner data, and improve patient acceptance and engagement.